Cellectar Biosciences (FRA:NV4) Total Assets : €39.48 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Cellectar Biosciences Total Assets?

Cellectar Biosciences's Total Assets for the quarter that ended in Mar. 2024 was €39.48 Mil.

During the past 12 months, Cellectar Biosciences's average Total Assets Growth Rate was 33.50% per year. During the past 3 years, the average Total Assets Growth Rate was 18.90% per year. During the past 5 years, the average Total Assets Growth Rate was 5.40% per year. During the past 10 years, the average Total Assets Growth Rate was -9.80% per year.

During the past 13 years, Cellectar Biosciences's highest 3-Year average Total Assets Growth Rate was 247.50%. The lowest was -56.60%. And the median was -6.70%.

Total Assets is connected with ROA %. Cellectar Biosciences's annualized ROA % for the quarter that ended in Mar. 2024 was -314.23%. Total Assets is also linked to Revenue through Asset Turnover. Cellectar Biosciences's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Cellectar Biosciences Total Assets Historical Data

The historical data trend for Cellectar Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Total Assets Chart

Cellectar Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

11.03

48.22

32.92

20.38

11.07

Cellectar Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															13.86	6.01	20.19	11.07	39.48

Cellectar Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Cellectar Biosciences's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	-1.243	+	12.317
	=	11.07

Cellectar Biosciences's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	24.073	+	15.403
	=	39.48

Cellectar Biosciences (FRA:NV4) Total Assets Explanation

Total Assets is connected with ROA %.

Cellectar Biosciences's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-79.42	/	( (11.074	+	39.475)	/ 2 )
	=	-79.42	/	25.2745
	=	-314.23 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Cellectar Biosciences's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (11.074	+	39.475)	/ 2 )
=	0	/	25.2745
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Cellectar Biosciences Total Assets Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectar Biosciences (FRA:NV4) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (FRA:NV4) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

CLRB:USA

Address

100 Campus Drive, Florham Park, NJ, USA, 07932

Website

https://www.cellectar.com

Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Cellectar Biosciences (FRA:NV4) Headlines

No Headlines